Vitalgen's Gene Therapy VGN-R09b Granted Priority Review by China's CDE for Treatment of Rare Pediatric Disease AADCD

Shanghai Vitalgen BioPharma Co., Ltd. has secured a major regulatory milestone for its gene therapy candidate VGN-R09b, as China's Center for Drug Evaluation (CDE) formally placed the drug into its priority review and approval program for the treatment of aromatic L-amino acid decarboxylase deficiency (AADCD) — a fatal pediatric rare disease with no approved cure.

The move, publicly announced on June 8, 2026, follows Vitalgen's new drug application (NDA) submission on June 5, 2026, filed through its affiliate Shanghai Taichang Biotechnology Co., Ltd. According to the CDE's priority review disclosure, the drug qualified under two criteria: as a novel pediatric drug formulation meeting children's physiological characteristics, and as a product previously designated under the breakthrough therapy program.

VGN-R09b is an adeno-associated virus (AAV)-based gene therapy delivered via a single intraparenchymal brain injection. The therapy is designed to precisely deliver the target gene to enhance dopamine synthesis in the brain while simultaneously promoting neuroprotection — a dual mechanism that Vitalgen says could address the root cause of AADCD rather than merely managing symptoms.

If approved, VGN-R09b would become the first gene therapy product for AADCD in China, filling a significant treatment void for patients with this devastating condition. The company has already aligned with the CDE on the scope of data supporting its marketing application, a critical step that signals the regulatory path toward commercialization is well defined.

The road to this point has been marked by a series of regulatory designations across both Chinese and U.S. authorities. Vitalgen first submitted two clinical trial applications for VGN-R09b to the CDE on January 25, 2024 — one for primary Parkinson's disease and one for AADCD — receiving implicit clinical approval in April 2024. The U.S. Food and Drug Administration (FDA) subsequently cleared the drug for clinical investigation in Parkinson's disease in July 2024.

Regulatory momentum accelerated in 2025. The CDE included VGN-R09b in its Breakthrough Therapy Designation (BTD) list for AADCD in November 2025, and the FDA granted Rare Pediatric Disease Designation (RPDD) for the same indication shortly thereafter. In June 2025, the FDA awarded Fast Track Designation (FTD) for VGN-R09b in primary Parkinson's disease. Most recently, in January 2026, the FDA granted Orphan Drug Designation (ODD) for the AADCD indication.

Clinical data reported by Vitalgen has been encouraging. For AADCD, the therapy has demonstrated favorable tolerability with no drug- or surgery-related serious adverse events observed. Notably, all subjects showed overall efficacy trends that significantly outperformed currently marketed products for the same indication abroad, according to the company.

For primary Parkinson's disease, VGN-R09b's pivotal Phase I/II registrational trial has completed at least six months of follow-up for all enrolled subjects. Preliminary data suggest the therapy not only has the potential to sustainably improve motor symptoms in patients with mid-to-late stage Parkinson's disease, but also shows promising signals of slowing disease progression — a finding that could have profound implications for a condition affecting millions worldwide.

The priority review designation in China typically compresses the standard review timeline, potentially bringing VGN-R09b to market faster than the conventional approval pathway. For patients with AADCD — a rare genetic disorder that impairs the production of critical neurotransmitters and leads to severe motor and developmental deficits — the timeline could be a matter of life and death.

Vitalgen's dual-track regulatory strategy, pursuing approvals in both China and the United States across two distinct indications, positions the company at the forefront of the gene therapy race for neurological rare diseases. The convergence of breakthrough therapy designation, orphan drug status, fast track designation, and now priority review across multiple jurisdictions underscores the unmet medical need and the therapeutic promise of VGN-R09b.